Parenteral administration of GM1 ganglioside to presenile Alzheimer patients
- PMID: 2330815
- DOI: 10.1111/j.1600-0404.1990.tb00930.x
Parenteral administration of GM1 ganglioside to presenile Alzheimer patients
Abstract
The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 +/- 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 mumol/l were found in 3 patients. The elimination half-life from serum was 60-75 h.
Similar articles
-
Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers.Clin Pharmacol Ther. 1991 Aug;50(2):141-9. doi: 10.1038/clpt.1991.118. Clin Pharmacol Ther. 1991. PMID: 1868675 Clinical Trial.
-
Pharmacokinetics of GM1 ganglioside following parenteral administration.J Pharm Pharmacol. 1990 Oct;42(10):708-11. doi: 10.1111/j.2042-7158.1990.tb06564.x. J Pharm Pharmacol. 1990. PMID: 1982143
-
Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.Dement Geriatr Cogn Disord. 1997 Jan-Feb;8(1):26-33. doi: 10.1159/000106597. Dement Geriatr Cogn Disord. 1997. PMID: 8997549 Clinical Trial.
-
Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease.Life Sci. 1994;55(25-26):2125-34. doi: 10.1016/0024-3205(94)00393-9. Life Sci. 1994. PMID: 7997071 Review.
-
Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives.Ann N Y Acad Sci. 1993 Sep 24;695:314-7. doi: 10.1111/j.1749-6632.1993.tb23074.x. Ann N Y Acad Sci. 1993. PMID: 8239303 Review.
Cited by
-
Advances in the pharmacotherapy of Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 1994;244(5):261-71. doi: 10.1007/BF02190379. Eur Arch Psychiatry Clin Neurosci. 1994. PMID: 7893772 Review.
-
A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28. J Neurol Sci. 2013. PMID: 23199590 Free PMC article. Clinical Trial.
-
GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular Route.Int J Mol Sci. 2020 Apr 19;21(8):2858. doi: 10.3390/ijms21082858. Int J Mol Sci. 2020. PMID: 32325905 Free PMC article.
-
Cognitive enhancement therapy for Alzheimer's disease. The way forward.Drugs. 1997 May;53(5):752-68. doi: 10.2165/00003495-199753050-00003. Drugs. 1997. PMID: 9129864 Review.
-
Glycosphingolipids.Adv Exp Med Biol. 2021;1325:61-102. doi: 10.1007/978-3-030-70115-4_3. Adv Exp Med Biol. 2021. PMID: 34495530
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical